Approved indications: In the United States, Ocrevus Zunovo is approved for adults with relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS) and with primary progressive MS.

Off-label uses: Because it is a subcutaneous formulation of ocrelizumab, some clinicians may consider Ocrevus Zunovo in place of IV Ocrevus in select, closely supervised situations where ocrelizumab might otherwise be used off label, but robust evidence and formal guidelines are lacking and routine use is generally limited to its approved MS indications.

Efficacy expectations: In the phase 3 OCARINA II trial, subcutaneous Ocrevus Zunovo achieved ocrelizumab blood levels and control of relapses and MRI lesions comparable to IV Ocrevus, with about 97% suppression of relapse activity and new MRI lesions over 48 weeks; many patients experience fewer relapses within the first year and a slowing of disability progression with continued treatment.

Comparison with similar drugs: Compared with IV Ocrevus, Ocrevus Zunovo offers similar high efficacy with a much shorter, twice-yearly 10-minute abdominal injection but more local injection-site reactions, while its relapse and MRI benefits are in the same high-efficacy range as other potent MS therapies (such as ofatumumab or natalizumab), though each option differs in dosing frequency, monitoring needs, and specific safety risks.

Typical dosing and how it is given: For adults with relapsing or primary progressive MS, the usual regimen is 920 mg ocrelizumab with 23,000 units hyaluronidase given as a single 23 mL subcutaneous injection into the abdomen over about 10 minutes once every 6 months, prepared and administered only by a healthcare professional.

Before each dose and special instructions: Before starting, patients are screened for hepatitis B and baseline blood tests such as immunoglobulin levels and liver enzymes; before every injection, the team checks for active infections, gives oral premedication (for example dexamethasone or another corticosteroid plus an antihistamine, with optional acetaminophen) at least 30 minutes beforehand, and then monitors the patient during and after the injection—at least 1 hour after the first dose and at least 15 minutes after later doses—for injection reactions.

Missed doses and overdose: If a scheduled injection is missed, it should be rescheduled and given as soon as possible rather than waiting for the next 6‑month date, and the following dose is then planned 6 months after the actual injection (with at least 5 months between doses); in the rare event of an overdose or doses given too close together, there is no specific antidote, so patients are monitored closely and treated supportively, and urgent medical care or poison control advice should be sought if overdose is suspected.

Common side effects (usually mild to moderate): The most common problem is injection reactions (about half of patients), including redness, pain, swelling, itching, or bruising where the medicine is injected, and sometimes headache or nausea shortly after the dose; upper or lower respiratory tract infections (such as colds, bronchitis) and skin infections also occur more often than in people not receiving ocrelizumab.

Serious or rare adverse effects: Serious infections (bacterial, viral, fungal, including herpes infections and possible hepatitis B reactivation) can occur and may rarely be life-threatening; very rare cases of progressive multifocal leukoencephalopathy (PML, a severe brain infection) have been reported with ocrelizumab, and there is a small but important concern for increased risk of cancers, particularly breast cancer, immune-mediated colitis (severe diarrhea and abdominal pain), liver injury, severe allergic or anaphylactic reactions, and prolonged low immunoglobulin levels that can predispose to recurrent infections.

Warnings and precautions: Ocrevus Zunovo must not be used in people with active hepatitis B infection or with a past life-threatening reaction to ocrelizumab or to hyaluronidase; it is not known to be safe or effective in children, and older adults or those with chronic lung, liver, or other immune-suppressing conditions may have higher infection risk; women who can become pregnant should use effective contraception during treatment and for 6 months after the last injection, discuss pregnancy plans and breastfeeding with their clinician, and avoid live vaccines during treatment and until B cells have recovered.

Relative safety compared with other MS drugs: Overall, the safety profile of Ocrevus Zunovo is very similar to IV Ocrevus, with the main difference being more local injection reactions, and its infection and malignancy risks are comparable to other B-cell–depleting therapies but generally differ from risks seen with sphingosine-1-phosphate modulators or natalizumab.

Side-effect reporting and safety updates: Patients should promptly report any new or worsening side effects to their prescriber, and in the United States side effects can also be reported directly to the FDA through the MedWatch program (online or by calling 1-800-FDA-1088) or to Genentech; current safety information and updates are available in the full prescribing information and Medication Guide and on the official Ocrevus website.

Drug and vaccine interactions: Ocrevus Zunovo does not significantly affect liver drug-metabolizing enzymes, so classic pill–pill interactions are uncommon, but its immune-suppressing effect can add to the effects of other immunosuppressive or immunomodulating drugs (such as long-term steroids, chemotherapy, other biologics, or potent small-molecule MS therapies), increasing infection risk; live or live-attenuated vaccines should not be given during treatment or until B cells have recovered, and it is recommended that needed non-live vaccines be updated at least 2–4 weeks before starting therapy.

Food, alcohol, and procedure considerations: There are no known direct interactions with specific foods, and moderate alcohol intake has no documented pharmacokinetic interaction, but heavy drinking may further increase infection and liver risks; Ocrevus Zunovo does not interfere with routine imaging tests or contrast dyes, though regular MRI scans are often used to monitor MS disease activity.

Conditions and co-medications requiring caution: Extra care is needed in people with prior or current hepatitis B, a history of recurrent or severe infections, chronic lung or heart disease, inflammatory bowel disease, prior malignancy (especially breast cancer), or significantly low immunoglobulin levels; combining this drug with other strong immune-suppressing agents, including some cancer therapies or long-term high-dose steroids, should be done only when the benefits clearly outweigh the added infection risk.

Monitoring during treatment: Before the first dose and periodically thereafter, clinicians typically check hepatitis B status, complete blood counts, quantitative immunoglobulin levels, and liver enzymes, watch for signs of infections or neurologic changes that could suggest PML, and may obtain periodic MRIs; B-cell counts and more detailed immune testing are sometimes used in complex cases to guide interval adjustments or evaluate safety concerns.

Q: How is Ocrevus Zunovo different from regular IV Ocrevus?
A: Ocrevus Zunovo contains the same active MS medicine (ocrelizumab) combined with hyaluronidase so it can be given as a 10-minute injection under the skin twice a year instead of a multi-hour IV infusion, with similar efficacy but more local injection reactions and no IV line.

Q: How long does it take for Ocrevus Zunovo to start working?
A: The medicine begins depleting B cells soon after the first injection, but its benefits are usually seen over months, with many people having fewer relapses and stable or improved MRI scans within the first year of treatment.

Q: Will I need to take Ocrevus Zunovo for life?
A: Ocrevus Zunovo is intended as a long-term, twice-yearly treatment as long as it continues to control your MS and remains safe for you, and decisions about continuing, stopping, or switching are based on ongoing discussion with your neurologist.

Q: Can I get vaccines while I am on Ocrevus Zunovo?
A: You should complete needed vaccines before starting treatment whenever possible, avoid live vaccines during therapy and until your B cells have recovered, and coordinate the timing of non-live vaccines (such as flu, COVID-19, and shingles) with your MS team because responses may be blunted.

Q: Is Ocrevus Zunovo safe during pregnancy or breastfeeding?
A: Because it can cross the placenta and affect the baby’s B cells and its transfer into breast milk is not fully known, it is generally recommended to use reliable contraception during treatment and for 6 months after the last dose and to carefully discuss pregnancy or breastfeeding plans with your neurologist and obstetric provider before each injection.

Storage: Ocrevus Zunovo vials are normally stored by healthcare professionals in a refrigerator at 36°F–46°F (2°C–8°C) in the original carton, protected from light, and must not be frozen or shaken.

If you are asked to keep vials at home (uncommon): store them in their original carton in the refrigerator, keep them out of the reach of children and pets, do not freeze or shake them, and do not use them after the expiration date or if the carton or vial is damaged.

Disposal: Any unused or expired Ocrevus Zunovo and all used syringes, needles, and tubing should be returned to your clinic, a sharps container program, or a pharmacy take-back site; do not place them in household trash or recycling and do not flush medicines down the toilet or sink.